Group items matching

in title, tags, annotations or url

People in the UK are increasingly relying on community pharmacies for health advice and support as they are unable to access their general practitioner (GP). According to a recent report by the Liberal Democrats, there was a significant increase in the number of patients waiting four weeks or more to see a GP in England last year, rising from 12.8 million in 2022 to 17.6 million. Responding to this research report, the Royal College of General Practitioners (RCGP) highlighted that GPs are also struggling to meet the increasing demand for their services due to severe staff shortages. Dr. Victoria Tzortziou-Brown, Vice Chair of the RCGP, stated that the average number of patients each GP is responsible for has increased by 158 compared to five years ago. Although she acknowledged that many patients are forced to wait for weeks to see their GP, she said that doctors too are grappling with "unmanageable and unsustainable workloads" and "we can't keep doing more with less."

The Royal Pharmaceutical Society (RPS) has released findings from its fifth annual workforce wellbeing survey, which was conducted in collaboration with the profession's charity, Pharmacist Support. Exposing the mental health challenges faced by pharmacists, the survey revealed a troubling statistic: 86 per cent of pharmacists are at a high risk of burnout. Inadequate staffing was the main factor contributing to burnout, followed by lack of work-life balance, insufficient protected learning time, absence of colleague or senior support, and long working hours. While pharmacies are encouraged to provide more clinical services, more than 60 per cent of pharmacists surveyed reported that they were not being offered "sufficient protected learning time" to focus on their professional development and learning needs. The survey also exposed a distressing trend of workplace abuse, with over 40 per cent of pharmacists reporting verbal abuse from the public, and 25 per cent from colleagues or managers.

Pharmacy sales specialist, Hutchings Consultants has revealed its market predictions for the next 12 months in a new report. The broker is anticipating that both independent group operators and corporate owners will continue to reassess their existing portfolios in 2024, making strategic disposals of varying sizes. "This is likely to result in transaction volumes remaining high for the foreseeable future," stated the report authored by Paul Steet, Associate Director, Hutchings Consultants. Community Pharmacy Contractual Framework negotiations will be the most notable opportunity for the sector to capitalise upon this year, the broker said, adding that it's "a belated opportunity for the sector to secure a vital uplift to the contract's fixed global sum."

With 118 new cases confirmed by the UK Health Security Agency (UKHSA), the total number of measles cases reported in England since 1 October 2023 has gone up to 465. According to the latest data published by the agency, West Midlands continues to see a disproportionately high rate of infections, with a sharp rise in case numbers over the last six weeks, mainly driven by cases in Birmingham. In England, there were 17 laboratory-confirmed measles cases in October, 42 in November, 161 in December, 240 in January 2024. Five more cases were confirmed last week, according to the measles statistics updated by UKHSA on 8 February. More than 70 per cent (329 of 465) of total confirmed cases were reported from the West Midlands, 13 per cent (62 of 465) from London, seven per cent (32 of 465) in Yorkshire and The Humber, and the remaining cases from other regions of England.

To maximise the benefits of the Pharmacy First service for patients, the NHS, and community pharmacies, Community Pharmacy England (CPE) has advised the community pharmacists to to establish a robust relationship between community pharmacies and local general practices. The news comes after several reports highlighted issues regarding GP referrals for the seven minor ailment conditions under the Pharmacy First services. According to the reports, many pharmacists claimed that "many GPs in England are not sending patients to them to be treated - and that some are refusing to participate at all in the "groundbreaking" Pharmacy First scheme". In response to foster better relationship with the GPs, CPE has said that strong local collaborations will enable general practice teams to confidently refer patients to the Pharmacy First and other community pharmacy services where appropriate. Moreover, the organisation emphasised implementation of long-term changes in practice will take time. The current focus on integrating GP referrals to Pharmacy First will likely require sustained effort over several months or longer.

The U.S. Food & Health Supplement Stores Industry-Industry & Market Report, published annually by Barnes Reports, contains timely and accurate industry statistics, forecasts and demographics. The report features 2013 current and 2014 forecast estimates on the size of the industry (sales, establishments, employment) nationally and for all 50 U.S.

Hair Care in Slovenia report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2008-2012, allowing you to identify the sectors driving growth. Forecasts to 2017 illustrate how the market is set to change.

Pompe Disease - Pipeline Review, H1 2012', provides an overview of the Pompe Disease therapeutic pipeline. This report provides information on the therapeutic development for Pompe Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pompe Disease. 'Pompe Disease - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Includes latest collection of China Agricultural science research and test development industry companies with annual revenue above 5 million USD.

Ear Care in Croatia report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2008-2012, allowing you to identify the sectors driving growth. Forecasts to 2017 illustrate how the market is set to change.

Oral Care in Saudi Arabia report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2008-2012, allowing you to identify the sectors driving growth. Forecasts to 2017 illustrate how the market is set to change.

In recent NIH Alzeimer's cognitive decline prevention report, it has been observed that Cognitive training identified as protective factor, with highest evidence. Read more at sharpbrains.com

Consumption of salt, it states both the positive and negative sides of salt and adds some research reports to add more impact to the writing

Consumption of salt, it states both the positive and negative sides of salt and adds some research reports to add more impact to the writing

Zenoti is an all-in-one, cloud software used by spas, salons, med spas, yoga and fitness studios to grow and manage their business. Our centralized platform integrates appointment scheduling, billing, marketing, inventory, custom reporting and mobile apps. Zenoti Mobile brings simplicity to the complexity of running your business. Staff have an easy to use system and are able to elevate the customer experience. Built-in marketing features help keep your appointment book full, and other capabilities automate many aspects of operations. Zenoti's enterprise platform is designed for the multi-location business with rich reporting, corporate level controls and more. Other Zenoti features include digital consultation forms, inventory management and enterprise custom reporting.

Future Market Insights has announced the addition of the "Delivery and Takeaway Food Market: Global Industry Analysis and Opportunity Assessment 2017-2027" report to their offering.

BioFit is an all-natural dietary supplement created for people who are unable to lose weight. It's a blend of chosen probiotics that's generally needed to keep your metabolism in good shape. Because metabolism influences all physiological systems, taking these probiotics is predicted to improve a person's overall health and quality of life. If you use the BioFit probiotic supplement, you may not need to go on a diet or engage in intense exercise to lose weight. Taking one probiotic pill per day can help you lose weight naturally.

Pharmacies and other spaces should be able to facilitate the provision of health care to bring services closer to patients and reduce demands on general practice, suggested a report by Tony Blair Institute. In a paper 'Modern and Sustainable NHS Providing Accessible and Personalised Care for All', it has propose six areas for reform where radical-but-practical policy action will begin to transform the future of the NHS and deliver better patient care. It has proposed to create new access routes for services and providers. It added: "The range and availability of health-care services must increase to reflect citizens' demands and their increasingly complex needs. "Pharmacies, gyms, supermarkets, workplaces and other spaces should all be able to provide or facilitate the provision of health care, bringing services closer to patients and reducing demands on general practice. It suggested: "We must move towards greater community-based care and the creation of a neighbourhood health service, with more routes for direct patient access, to ensure services are available when and where people need them. These should all be accessible through a single, simple digital front door to the NHS."

The NHS is on track to miss out on savings of over a billion pounds as patents for a new lineup of 85 biologics are set to expire within the next five years, the British Generic Manufacturers Association has revealed in its new study. The government's Voluntary Scheme for Branded Medicines Pricing and Access is expected to lead to a cost of more than £1 billion for the NHS in the coming years. The BGMA research found that more than 85 biological medicines will experience loss of exclusivity during the upcoming VPAS Scheme period from 2024 to 2028. "This includes blockbuster products like the cancer medicine Keytruda and wet macular product Eylea, which together generate approximately $25 billion in global sales," BGMA said. "The molecules coming off-patent also cover other disease areas including oncology, diabetes, arthritis, and asthma." While biological medicines dominate the medicines budget, constituting the largest cost and cost growth sectors, NHS England aims to expedite biosimilar availability, yielding substantial savings and expanding patient access to vital treatments. Yet, the report found that "this is jeopardised by the influence of the VPAS Scheme".

A policy brief, developed by researchers from the University of Bath and University of Strathclyde with funding from Sigma Pharmaceuticals, has recommended the Department of Health and Social Care (DHSC) and NHS to increase community pharmacy funding to avoid damaging closures and diminution of quality. The report launched on Wednesday (12 June) at an event in the House of Commons, attended by Members of Parliament, senior policymakers and the pharmacy industry, analysed community pharmacy policies and spoke to stakeholders to explore their opinions of the future of community pharmacy. It was found that patients value their community pharmacies, but staff feel demotivated, insecure and undervalued. Stakeholders and policies suggested that in the future, medicines should be supplied by automated 'hub and spoke' dispensing, enabling community pharmacy staff to provide services that relieve pressure on GP surgeries, such as long-term conditions management, urgent care and public health.

Approximately 25 million GP appointments and 5 million A&E visits are utilised each year for self-treatable illnesses. If these individuals chose to self-treat using over-the-counter (OTC) medications, the potential savings for NHS could amount to at least £1.7 billion annually, according to a research commissioned by Proprietary Association of Great Britain. The study, conducted by analysts at Frontier Economics, revealed that embracing self-care could bring an additional economic benefit of £350 million annually, as employees would avoid unnecessary time off from work for medical appointments. Apart from the savings resulting from the increased OTC medicine use, the report emphasises the potential benefits of reclassifying more prescription-only medications (POMs). A mere 5 per cent reduction in NHS prescribing levels and spending could lead to an annual cost-saving of £1.4 billion, encompassing both prescription costs and GP appointments, it said. "This substantial amount could greatly alleviate financial pressures on the NHS and offer essential resources for recruiting and training much-needed healthcare professionals."